review here the current understanding of the molecular mechanisms by which antithrombin regulates blood clotting proteinases since it provides a useful paradigm for understanding the complex modes by which serpins regulate proteinase activity. We will first consider the means by which antithrombin achieves specificity for its target proteinases and second discuss how heparin brings about activation of the serpin.
Mechanism of proteinase inhibition-Antithrombin inhibits its target proteinases by an
unusual branched pathway suicide substrate mechanism that is shared by other serpin family inhibitors of proteinases ( Fig. 1 ) [1] . Notable among the serpins is their use of both a substrate recognition sequence contained within an exposed reactive center loop (RCL) as well as exosite recognition determinants outside the RCL to lure the proteinase to form an initial Michaelis-like complex (Fig. 2) [8]. In the case of antithrombin, a P1 Arg and flanking residues provide the "bait" substrate sequence recognized by the trypsin-like serine proteinases of the blood clotting cascade.
Additionally, attractive and repulsive exosites exist outside this sequence whose differential accessibility in repressed and glycosaminoglycan-activated states of the serpin allows regulation of proteinase binding [9] . Once the proteinase is bound, its catalytic serine proceeds to attack the reactive P1 Arg bond in the serpin RCL, resulting in the formation of an acyl-intermediate complex in which the RCL has been cleaved but remains covalently linked to the catalytic serine through the P1 residue. The cleavage triggers the suicide mechanism by freeing the metastable serpin to undergo a massive conformational change in which the cleaved RCL inserts into the center of a 5-stranded β-sheet, the A sheet, causing the tethered proteinase to be dragged to the opposite end an increased risk of thrombosis [6] . The heparan sulfate molecules that line the surface of blood vessel endothelial cells are thought to activate circulating antithrombin and thereby to be responsible for the unusual nonthrombogenic properties of the vessel wall [13, 14] . Since blood clotting is activated and localized at the site of an injured vessel, luminal and subluminal endothelial cell heparan sulfate molecules are thought to activate antithrombin anticoagulant function at such sites. Heparin released from extravascular mast cells closely associated with blood vessels may additionally activate antithrombin at these sites. This would allow antithrombin to rapidly inactivate blood clotting proteinases that escape from an injury site and prevent the dissemination of blood clots away from the injury.
Heparin and heparan sulfate allosterically activate antithrombin by binding the serpin through a common sequence-specific pentasaccharide and inducing activating conformational changes in the protein (Figs. 3-5) [15, 16] . The binding is of high affinity, with a dissociation constant of ~50 nM at physiologic pH and ionic strength [17] . The pentasaccharide is responsible for the bulk of the binding energy of full-length heparin and heparan sulfate chains, the longer glycosaminoglycans binding antithrombin with ~3-fold higher affinity than the pentasaccharide. The full-length glycosaminoglycans may additionally activate antithrombin as bridging cofactors by binding both the serpin and proteinase and promoting their interaction in a ternary complex (Fig. 3 ) [18] . While allosteric activation by the sequence-specific heparin pentasaccharide selectively enhances antithrombin reactivity with factors Xa and IXa, the bridging effect of fulllength glycosaminoglycan chains augments antithrombin reactivity with factors Xa and IXa and is solely responsible for upregulating antithrombin reactivity with another important target proteinase, thrombin [17, 19] .
Conformational changes induced in antithrombin by allosteric activation-The molecular details of the allosteric activation mechanism have been suggested by X-ray crystal structures of antithrombin free and complexed with the heparin pentasaccharide (Fig. 5 ) [20, 21] . The heparin binding site on antithrombin is comprised of three distinct regions of the protein that come together in the tertiary structure, namely, the N-terminal region, the N-terminal end of helix A and all of helix D together with its N-terminal loop (Fig. 6 ).
Positively charged basic residues in each of these regions, including Lys11, Arg13, Arg46, Arg47, Lys114, Lys125 and Arg129, interact through ionic and hydrogen bonds with negatively charged sulfate and carboxylate groups on the heparin pentasaccharide.
Comparison of free and heparin complexed antithrombin structures further reveals significant conformational changes in the protein induced by heparin binding (Figs. 5 & 6) [21] . These conformational changes are more limited than those induced by proteinase reaction but nevertheless involve significant structural rearrangements both in the heparin binding site and in the region surrounding the RCL where the proteinase binds. In the heparin binding site, the N-terminus and helix A undergo large reorientations to widen the binding site and position basic residues for interaction with pentasaccharide groups. Additionally, helix D rotates, the C-terminal end of helix D extends and a new P helix is formed in the loop preceding this helix, resulting in the repositioning of basic residues in these regions for interaction with pentasaccharide groups. In the proteinase binding RCL region, a major structural change occurs in which the RCL, initially buried through its N-terminal hinge in a partially open sheet A, is expelled from the sheet and extended away from the serpin body. The hydrogen bonding network and hence the surface electrostatics in the region surrounding the RCL is further altered [22] . These structural changes are responsible for the allosteric activation of antithrombin reactivity toward factors Xa and IXa by mechanisms discussed further below. The expulsion of the RCL from sheet A appears to be driven by a closing of the gap in sheet A that is in turn linked to the C-terminal extension of helix D in the heparin binding site [23, 24] . Helix D extension thus produces a shortening of the loop that connects the helix to strand 2 of sheet A as well as a compaction of the hydrophobic core to cause the contraction of the sheet. In this way, the conformational changes in the heparin binding site are transmitted to the proteinase binding site to induce activation of the serpin.
Mechanism by which allosteric activation enhances antithrombin reactivity-How the conformational changes induced in the proteinase binding region by the heparin pentasaccharide activate antithrombin reactivity with proteinases has been the subject of numerous studies. It was initially thought that RCL expulsion from sheet A made the RCL more accessible to target proteinases and that this increased accessibility accounted for the activating effect of heparin on antithrombin reactivity [25] . However, such a mechanism failed to explain why heparin allosteric activation was selective in enhancing antithrombin reactivity with two target proteinases, factor Xa and factor IXa, and minimally enhanced antithrombin reactivity with thrombin. That the RCL did not contain the determinants responsible for heparin activation of antithrombin reactivity with proteinases was shown by experiments in which the RCL bait sequence was altered by mutagenesis to create an optimal thrombin recognition sequence [19, 26] .
This had the expected result of greatly increasing antithrombin reactivity with thrombin and decreasing reactivity with factors Xa and IXa, but unexpectedly, such changes affected basal antithrombin reactivity and had no effect on the selectivity or magnitude of heparin pentasaccharide enhancements of antithrombin reactivity with the three proteinases. Another series of experiments showed that changing the P1 Arg bait residue greatly reduced antithrombin reactivity with all target proteinases, but again had no effect on the differential heparin enhancements of antithrombin reactivity with the proteinases [27] . Such studies revealed the importance of exosite determinants outside the RCL in mediating heparin activation of antithrombin [28] .
Identification of exosites that specifically interacted with factors Xa and IXa was accomplished by engineering chimeric antithrombins in which secondary structural regions that define the surface of the serpin from which the RCL protrudes were swapped with those of α 1 -proteinase inhibitor, a serpin that is not activated by heparin [29] . Of the six chimeras prepared, only one, in which strand 3 of sheet C was substituted, showed a marked loss in the ability of heparin pentasaccharide to enhance antithrombin reactivity with factors Xa and factor IXa without affecting its reactivity with thrombin. Intriguingly, site-specific mutations in this region showed complex effects implying the existence of both favorable and unfavorable exosites in this region whose expression depended on heparin activation [30] . Notably, mutating two residues in strand 3C, Tyr253 and Glu255 that are highly conserved in vertebrate antithrombins but not in other serpins, closely duplicated the strand 3C chimera defect in factor Xa reactivity that was strictly dependent on heparin activation. However, mutating Tyr253 alone caused a comparable large loss in factor Xa reactivity but this loss was independent of heparin allosteric activation. These strand 3C mutations produced a similar pattern of losses in antithrombin reactivity with factor IXa that were dependent on heparin activation for the strand 3C chimera but did not depend on activation for single Tyr253 and Glu255 mutations. Such results have suggested a model of allosteric activation in which Tyr253 constitutes a key exosite residue that specifically interacts with factor Xa and factor IXa in both native and heparin-activated states (Fig. 7) [9].
However, other residues in strand 3C produce unfavorable interactions that attenuate the favorable Tyr253 interaction in native antithrombin. According to this model, heparin activates antithrombin reactivity by relieving the unfavorable interactions. That Tyr253 and Glu255 cooperate as positive factor Xa and IXa-specific interaction exosites in heparin-activated antithrombin is supported by the finding that changing the strand 3C homologues of these residues in a P1 Arg variant of α 1 -proteinase inhibitor to their antithrombin counterparts specifically enhances α 1 -proteinase inhibitor reactivity with factors Xa and IXa, but not with thrombin [31] .
Recent X-ray structures of Michaelis complexes of heparin-activated antithrombin with catalytic Ser-inactivated variants of factor Xa [32] , factor IXa [33] and thrombin [34, 35] support the importance of favorable exosite interactions identified by mutagenesis studies in mediating the enhanced reactivity of allosterically-activated antithrombin with factor Xa and factor IXa but not with thrombin (Fig. 7) . These structures clearly show that factors Xa and IXa bound to the antithrombin RCL are able to engage the exosites on strand 3 of sheet C surrounding the RCL that were identified by mutagenesis studies. The complementary exosites on the proteinases involve a critical conserved Arg 150 residue in the autolysis loop that binds in a pocket formed by the antithrombin exosites on strand 3C [36, 37] . Thrombin lacks the conserved Arg and therefore is not able to interact with the antithrombin exosites. Heparin allosteric activation thus minimally affects antithrombin reactivity with thrombin and the rate-enhancing effect of heparin is solely due to the ternary complex bridging mechanism.
Based on the X-ray structures of the Michaelis complexes showing the expected expulsion and extension of the RCL away from sheet A that is characteristic of heparinactivated antithrombin, it has been proposed that RCL expulsion is essential for bound factors Xa and IXa to engage the strand 3C exosites and that this is the key activating event required for allosteric activation [32, 33] . One problem with this proposal is that it fails to account for the repulsive determinants in strand 3C that are inferred to repress antithrombin reactivity in the absence of heparin activation. The model of allosteric activation discussed above that accounts for this and much other data suggests instead that favorable exosite interactions are already engaged in native antithrombin but are diminished by unfavorable interactions. Activation in this case involves the mitigation of the unfavorable interactions, with RCL expulsion contributing to but not being required for such activation (Fig. 8) . Much other data favor this latter activation model over the former. One key observation is that Cα-Cα distances between P1Arg and the Tyr253 exosite in free antithrombin are no greater than those in the heparin-antithrombin-factor Xa Michaelis complex, implying that factor Xa bound to the RCL is just as accessible to the strand 3C exosites in the RCL-inserted native state as it is in the RCL-expelled activated state of the serpin. Additionally, the X-ray structure of a fluorescein-derivatized RCL hinge variant of antithrombin that is activated without the need for heparin shows the RCL backbone inserted into sheet A as in native antithrombin, implying that RCL expulsion and extension away from sheet A is not a requirement for activation and that alteration of the surface electrostatics may be the dominant activation mechanism [38] .
Recent evidence provides additional support for the model by showing that mutation of a buried Tyr131 in the C-terminal loop of helix D to Leu results in a pentasaccharide-independent partial activation of antithrombin reactivity with factor Xa without inducing the spectroscopic signature of RCL expulsion from sheet A, presumably through rearrangements in the hydrophobic core [39] . Moreover, a Lys133 to Pro mutation that blocks helix D extension shows a pentasaccharide-dependent partial allosteric activation of antithrombin without the spectroscopic changes that report RCL expulsion [24] . Together, these findings support the model in which factor Xa and factor IXa interact with both the RCL and the strand 3C exosites in native antithrombin, but unfavorable interactions result in a repressed reactivity with these proteinases.
Allosteric activation by heparin pentasaccharide enhances reactivity by changing the surface electrostatics so as to mitigate the unfavorable interactions and retain the favorable RCL and exosite interactions. Although recent reports show that blocking RCL expulsion from sheet A by an engineered disulfide abrogates heparin pentasaccharide activation of antithrombin [40] , the disulfide may have global effects that rigidify the allosteric core and block the activating changes observed in the Tyr131 and Lys133 mutants. Further reconciliation of these models of allosteric activation will require X-ray structures of unactivated antithrombin-factor Xa/IXa Michaelis complexes as well as mutagenesis studies that identify those antithrombin residues responsible for the proposed unfavorable interactions with factors Xa and IXa.
Antithrombin residues involved in binding the heparin pentasaccharide-Other studies
have focused on delineating the mechanism of heparin pentasaccharide binding to antithrombin and the activating conformational changes induced in the heparin binding site by this binding. Notably, mutagenesis of the antithrombin basic residues implicated in pentasaccharide binding by the X-ray structure have revealed that three of these residues, Lys125 and Arg129 in helix D and Lys114 in the P helix preceding helix D, represent binding hotspots since mutation of any one of these residues causes major losses in binding energy much greater than would be expected from loss of a single ionic interaction (Fig. 6) [41] [42] [43] . By contrast, Lys11 and Arg13 in the N-terminal region and Arg46 and Arg47 in helix A, make lesser contributions to binding affinity since mutation of any one of these residues causes a loss of binding energy that in most cases approximates the loss of a single ionic interaction [44, 45] . The three binding hotspot residues must therefore bind the pentasaccharide cooperatively. Recent work examining the binding energy losses resulting from single, double or triple mutations of the binding hotspot residues suggest a strong interdependence of Lys125 and Arg129 interactions that accounts for their cooperativity but an independence of Lys114 interactions implying that Lys114 cooperates with other basic residues [46] . Interestingly, all but Arg46, whose mutation causes the smallest decrease in heparin binding affinity, are highly conserved in the thirteen vertebrate sequences of antithrombin that are known, representing all five vertebrate families [47] .
Analysis of the ionic strength dependence of heparin pentasaccharide binding to antithrombin reveals that not only ionic interactions but also significant nonionic interactions make important contributions to the binding affinity [17] . A conserved triplet of Phe residues in helix D appears to be responsible for much of the nonionic binding energy due to the indirect role of at least two of these residues in stabilizing the activated conformation [48] . Proton NMR spectroscopic changes accompanying pentasaccharide activation of antithrombin support the idea that these and other aromatic residues comprise an allosteric communication network in the hydrophobic core through which structural changes in the heparin binding site are transmitted to the proteinase binding region [49] . Arg24 in the N-terminal region and Trp49 in helix A play similar indirect roles in heparin activation by making critical new intramolecular interactions in the activated state that stabilize this state [45, 50] .
Induced-fit model of allosteric activation-Insight into the dynamics of heparin
pentasaccharide binding and allosteric activation of antithrombin have come from rapid kinetic studies of the binding interaction [17, 51] . Such studies have shown that binding is a two-step process with an initial weak binding of heparin to antithrombin followed by the activating conformational changes in the protein that enhance binding affinity ~1000-fold and that are reported by CD, near UV and tryptophan fluorescence changes.
Notably, only Lys125, and to a lesser extent Lys11, contribute to the first weak heparin binding step whereas all other residues, including the key Lys114 and Arg129 binding residues, interact only after the second conformational activation step [16] . The interactions of Lys125 and Lys11 are also augmented after conformational activation.
These findings indicate that heparin pentasaccharide binding and allosteric activation of antithrombin is driven by an induced-fit mechanism wherein activation produces a complementary fit between antithrombin and the pentasaccharide that greatly enhances pentasaccharide binding affinity and overcomes the energetic barrier for transforming antithrombin into the less favored activated conformation (Fig. 9) . Notably, an alternative mechanism suggesting that activation is driven by heparin neutralizing positive charge in the heparin binding site has been refuted by the observation that replacing the positively charged residues with neutral or negatively charged residues fails to activate antithrombin basal reactivity with factor Xa or factor IXa [52] .
Parallel studies of the interaction of truncated pentasaccharide variants with antithrombin have confirmed and extended the induced-fit model of allosteric activation of the serpin [53] . Such studies have revealed that the nonreducing end trisaccharide of the pentasaccharide is the key unit that functions to recognize and bind native antithrombin and produce an induced-fit conformational activation of the serpin (Fig. 9) .
However, the trisaccharide shows a greatly reduced ability to stabilize the induced-fit (Fig. 4) [53] .
Evidence for a 3-step mechanism of allosteric activation-Further molecular dissection of the allosteric activation mechanism has come from recent studies of heparin pentasaccharide binding to conformationally altered latent and cleaved forms of antithrombin that have reduced affinity for the pentasaccharide [55] . Both latent and cleaved forms have undergone the massive conformational change induced by proteinase reaction in which the RCL has fully inserted into sheet A, the latent form differing from the cleaved form in having undergone this conformational change spontaneously without RCL proteolysis because of the greater thermodynamic stability of the RCL-inserted state [56] . Surprisingly, the kinetics of heparin pentasaccharide binding to the latent and cleaved antithrombin forms reveal a two-step induced-fit binding mechanism that is strikingly similar to the mechanism of pentasaccharide binding to native antithrombin. Thus, the affinity of the initial binding step and rate constant for the subsequent induced-fit conformational activation step are indistinguishable for pentasaccharide binding to native and latent/cleaved forms of antithrombin. The differences in the binding kinetics arise solely from large differences in the rate constant for reversal of the induced-fit conformational change, this rate constant reflecting the off-rate constant for pentasaccharide dissociation from activated antithrombin.
That a set of shared induced-fit structural changes accompany pentasaccharide binding to native and latent/cleaved antithrombin forms is supported by X-ray structures of free and heparin pentasaccharide complexes of latent antithrombin (Fig. 10) [20, 21] .
These structures were obtained from the corresponding crystal structures of native antithrombin since antithrombin crystallizes as a dimer between native and latent forms.
In the pentasaccharide complex structures, latent antithrombin is bound to the pentasaccharide at the same site and with similar contacts as native antithrombin. [40, 58] , i.e., the changes resemble those observed in the latent antithrombin-pentasaccharide complex (Fig. 10) .
Interestingly, the mutant antithrombin in which Lys133 in the C-terminal extension of helix D is replaced by a Pro to block helix D extension shows an affinity and kinetics of pentasaccharide binding that differ from native antithrombin only in the off-rate constant in exactly the same manner as the interaction with latent antithrombin [24] . Unlike the latent antithrombin interaction, the Lys133Pro variant is partially activated by pentasaccharide binding, implying that the conformational changes induced in the heparin binding site of the variant, and presumably also the intermediate, involve
activating changes in the proteinase binding site that do not require helix D extension and RCL expulsion from sheet A as discussed earlier.
Together, these observations suggest that the activating conformational changes induced by the heparin pentasaccharide in native antithrombin occur in two stages in an overall 3-step binding and activation mechanism (Fig. 9) [40] which the second conformational change is assumed to be much faster than the first (to account for the similar rates of conformational change caused by heparin binding to native and latent antithrombins) and the parameters are constrained so that the overall binding affinities agree with measured values indicate binding kinetics that are indistinguishable from a two-step mechanism [57] .
* This supports the 3-step mechanism for heparin binding to native antithrombin and implies that the two successive conformational changes are driven by progressive induced-fits that increase heparin affinity and lock the serpin in the activated state and thus account for the reduced heparin off-rate. The reason for what seems to be an overly complex design appears two-fold.
Model for allosteric activation of antithrombin by heparin-
First, it serves to repress antithrombin reactivity until it is needed either at the blood vessel wall to prevent surface-mediated activation of blood clotting proteinases or at an injury site to control and localize blood clotting proteinase activity. Second, it acts to prevent antithrombin reactivity with another anticoagulant serine proteinase, activated protein C [59] . This critical anticoagulant proteinase is activated by thrombin in a feedback loop for the purpose of shutting down thrombin formation. This is accomplished by activated protein C proteolytically inactivating the nonenzymatic cofactor proteins, factors Va and VIIIa, that are essential for thrombin formation. Since activated protein C cooperates with antithrombin to regulate hemostasis by preventing unwanted activation of blood coagulation, it would be counterproductive for antithrombin to inhibit activated protein C. Although activated protein C recognizes the P1 Arg bait of antithrombin, it is in fact inactivated by heparin-activated antithrombin at a nonphysiologic rate that is seven orders of magnitude slower than the rate at which target proteinases are inactivated [60] . This greatly compromised reactivity appears to arise from an unfavorable RCL sequence since it can be closely replicated when the antithrombin RCL is put into an α 1 -proteinase inhibitor scaffold with a P1 Arg [60] .
Antithrombin has thus evolved to selectively regulate procoagulant blood clotting 
